Volume 8, Issue 4 (11-2022)                   RABMS 2022, 8(4): 228-236 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kazemi Motlagh N, Hesami Tackallou S, Mahdavi M, Hosseinzadeh M. Evaluation of Cytotoxicity, Cell Cycle, and Apoptosis Induction of Methyl Thiosemicarbazone Complex with Copper on K562 Cell Line. RABMS 2022; 8 (4) :228-236
URL: http://ijrabms.umsu.ac.ir/article-1-208-en.html
Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran , Kevin.Hosseinzadeh@gmail.com
Abstract:   (31 Views)
Background & Aims:  Chronic human myeloid leukemia (CML) is caused by mutations and changes in stem cells. This study aimed to investigate the toxicity, apoptosis, and cell cycle of thiosemicarbazone complex with copper on the human chronic myelogenous K562 leukemia cell line.
Materials & Methods:  After culturing the human K562 cell line, it was exposed to the combination of methyl thiosemicarbazone complex with copper in different concentrations and durations. Trypan blue dye exclusion test and MTT were used to determine cell viability and cell growth inhibition. The occurrence of apoptosis was examined by dual acridine orange/ethidium bromide (AO/EB) fluorescent staining and fluorescence microscopy, cell cycle analysis, and dual PI/AnnexinV staining using flow cytometry.
Results:  The data obtained from the present study showed morphological changes resulting from apoptosis and cell cycle arrest in Sub G1 in the presence of phosphatidylserine in the outer leaflet of the cell membrane due to treatment with thiosemicarbazone compound. It also decreased the biological growth of the K562 cell line in a concentration-/ and time-dependent manner.
Conclusion:  effective at low concentrations and short duration of action, this compound can be a suitable candidate for future pharmacological studies on treating CML.
Full-Text [PDF 604 kb]   (40 Downloads)    
Type of Study: orginal article | Subject: Special

References
1. Madmoli M. Clinical and laboratory finding in children with leukemia: A systematic review. Int J Res Stud Sci Eng Tech 2018;5(10):1-6. [Google Scholar]
2. Moslemirad M, Madmoli M, Madmoli Y, Niksefat M. Prevalence of type 1 and type 2 diabetes and its related factors in diabetic patients hospitalized in Khatam-ol-Anbia hospital in Shoushtar, 2014-15: A retrospective study. J Res Med Dent Sci 2018;6(3):421-6.
3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018;93(3):442-59. [DOI:10.1002/ajh.25011] [PMID]
4. Kumar R, Krause DS. Recent advances in understanding chronic myeloid leukemia: where do we stand? Fac Rev 2021;10. [DOI:10.12703/r/10-35] [PMID] [PMCID]
5. Eden RE, Coviello JM. Chronic myelogenous leukemia. StatPearls [Internet]: StatPearls Publishing; 2020. [URL]
6. Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34(8):2074-86. [DOI:10.1038/s41375-020-0826-9] [PMID] [PMCID]
7. Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, et al. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines. Genom Proteom Bioinform 2014;12(2):79-91. [DOI:10.1016/j.gpb.2014.02.001] [PMID] [PMCID]
8. Hehlmann R, Cortes JE, Zyczynski T, Gambacorti‐Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol 2019;94(1):46-54. [DOI:10.1002/ajh.25306] [PMID] [PMCID]
9. Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology 2014, the American Society of Hematology Education Program Book. 2019;2019(1):433-42. [DOI:10.1182/hematology.2019000050] [PMID] [PMCID]
10. Singhal N, Bapsy P, Babu K, George J. Chronic myeloid leukemia. JAPI. 2004; 52:410-6. [URL]
11. Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002; 181:471-4. [DOI:10.1016/S0300-483X(02)00457-2] [PMID]
12. Qin Q-P, Chen Z-F, Qin J-L, He X-J, Li Y-L, Liu Y-C, et al. Studies on antitumor mechanism of two planar platinum (II) complexes with 8-hydroxyquinoline: synthesis, characterization, cytotoxicity, cell cycle and apoptosis. Eur J Med Chem 2015; 92:302-13. [DOI:10.1016/j.ejmech.2014.12.052] [PMID]
13. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86(17):1286-96. [DOI:10.1093/jnci/86.17.1286] [PMID]
14. Mbah JA, Ayimele GA, Eyonganyoh EN, Nfor EN. Synthesis, Molecular Structure and Antibacterial Activity of Benzylmethyl-4-Methyl-3-Thiosemicarbazone. Int J Org Chem 2017;7(02):83. [DOI:10.4236/ijoc.2017.72007]
15. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell viability assays. Assay Guidance Manual [Internet]. 2016. [URL]
16. Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. Checkpoint controls and cancer: Springer; 2004. p. 301-11. [DOI:10.1385/1-59259-811-0:301] [PMID]
17. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, et al. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 2009;52(17):5271-94. [DOI:10.1021/jm900552r] [PMID]
18. Prashar A, Siddiqui F, Singh AK. Synthetic and green vegetable isothiocyanates target red blood leukemia cancers. Fitoterapia 2012;83(2):255-65. [DOI:10.1016/j.fitote.2011.11.012] [PMID]
19. Xia Y, Liu X, Zhang L, Zhang J, Li C, Zhang N, et al. A new Schiff base coordinated copper (II) compound induces apoptosis and inhibits tumor growth in gastric cancer. Cancer Cell Intl 2019;19(1):1-11. [DOI:10.1186/s12935-019-0801-6] [PMID] [PMCID]
20. Hosseini-Yazdi SA, Mirzaahmadi A, Khandar AA, Eigner V, Dušek M, Mahdavi M, et al. Reactions of copper (II), nickel (II), and zinc (II) acetates with a new water-soluble 4-phenylthiosemicarbazone Schiff base ligand: Synthesis, characterization, unexpected cyclization, antimicrobial, antioxidant, and anticancer activities. Polyhedron 2017;124:156-65. [DOI:10.1016/j.poly.2016.12.004]
21. Koeffler H, Golde D. Human myeloid leukemia cell lines: a review. Blood 1980; 56 (3): 344-50. https://doi.org/10.1182/blood.V56.3.344.344 [DOI:10.1182/blood.V56.3.344.bloodjournal563344] [PMID]
22. Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs 2019;30(8):828-37. [DOI:10.1097/CAD.0000000000000780] [PMID]
23. Parsa FG, Feizi MAH, Safaralizadeh R, Hosseini-Yazdi SA, Mahdavi M. Molecular mechanisms of apoptosis induction in K562 and KG1a leukemia cells by a water-soluble copper (II) thiosemicarbazone complex. J Biol Inorg Chem 2020;25(3):383-94. [DOI:10.1007/s00775-020-01769-0] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb